Navigation Links
Alliqua Appoints Dr. Joseph Laudano as Vice President of Medical Affairs to Support the Market Expansion of Alliqua's SilverSeal Products and Future Clinical Development
Date:11/15/2012

NEW YORK, Nov. 15, 2012 /PRNewswire/ -- Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or the "Company"), an advanced biopharmaceutical company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies, today announced the appointment of Joseph Laudano, Pharm.D.  to the newly created position of Vice President, Medical Affairs to support the market expansion of Alliqua's SilverSeal® products  as well as other future clinical developments.  Dr. Laudano will lead the development of a medical affairs team at Alliqua  as the company now begins to step up the marketing efforts for our proprietary 510K  FDA approved SilverSeal® hydrogels for wound care.  He will also play a key role in the planning and clinical development of our platform for transdermal drug delivery

Commenting on the appointment, James Sapirstein, CEO of Alliqua stated, "We are very pleased to have an industry veteran of such high caliber join our team here at Alliqua.  One of my primary near term goals as CEO of this company is to put the right people in place that can deliver on the rich potential of our proprietary technology as well as our future strategic plans.  Joe has extensive experience in some key therapeutic areas such as dermatology and infectious diseases, which I believe align nicely with Alliqua's future needs as we build this organization."

Dr. Laudano joins Alliqua with more than twenty five years of experience in the pharmaceutical industry including four years as Senior Director of Medical Affairs at Forest Research Institute, a subsidiary of Forest Labs, and twenty years at Roche Laboratories. As Product Director at Roche he was responsible for strategic/tactical planning, business development, marketing and promotional activities for the diversified product portfolio which was comprised of 16 different brands including Xenical, Rocephin and Accutane.  He was also part of the team that launched the Roche Dermatologics division at Roche which was dedicated to the development and commercialization of systemic and topical retinoids along with other compounds.  He has extensive experience in Medical Affairs and product development, particularly with antimicrobial and dermatologic compounds, which will be critical to Alliqua as we move forward with the science to support its transdermal drug delivery platform and other future endeavors. 

Commenting on his new position, Dr. Laudano added, "I am thrilled to become a part of this exciting organization which I believe is entering a tremendous new phase of growth.  Having spent the better part of my career working with infectious disease products, I am very impressed with the data which sets SilverSeal apart from other hydrogel products.  There are numerous studies supporting the efficacy of silver dressings in wound management. Silver has broad spectrum activity against bacteria including MRSA, Pseudomonas, and other antimicrobial-resistant bacteria. Based on this activity and with the increase of infections more resistant to antibiotic treatments, dressings like our SilverSeal® hydrogels are perfectly positioned to capitalize on the growing need in the medical marketplace for alternatives for the management of open wounds in support of antimicrobial stewardship programs." 

About Alliqua, Inc.

Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing and distribution of our proprietary transdermal wound care and drug delivery technologies. Alliqua's leading technology platform produces hydrogels, a three dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations. We currently market our new line of 510K FDA approved hydrogel products for wound care under our SilverSeal® brand. Due to our electron beam production process at our 16,000 square foot GMP manufacturing facility, we can aggressively develop and custom manufacture a wide variety of hydrogels. Our hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds such as diabetic ulcers, as well as the delivery of numerous drugs or other agents for the pharmaceutical and cosmetic industries. By using our drug delivery platform in combination with certain drugs, pharmaceutical companies can increase patient compliance as well as potentially extend the life of valuable drug patents. For additional information, please visit www.alliqua.com. To receive future press releases via email, please visit: http://alliqua.com/index.php?page=investor-alerts.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.

Contact:

Alliqua, Inc.
Steven Berger
646-218-1450 

 


'/>"/>
SOURCE Alliqua, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Daniels Sharpsmart Canada Awarded HealthPro Contract And Appoints Daniel Kennedy CEO Of Daniels Canada
2. Discovery Labs Appoints John R. Leone to Board of Directors
3. Amarantus BioSciences Appoints Dr. Robert J. Zimmerman as Product Development Advisor
4. Cantel Medical Appoints Jorgen B. Hansen As Executive Vice President And Chief Operating Officer
5. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
6. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
7. Aushon BioSystems Appoints Bill Williams Vice President of Sales
8. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
9. Igenica Appoints Mary Haak-Frendscho, Ph.D., as Chief Executive Officer
10. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
11. Circassia Appoints Stewart Sharpe as Vice President Commercial Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2019)... ... 2019 , ... The 'W' Initiative, a flagship women empowerment ... Month. The plans are aimed at improving community awareness on health issues that ... health checks and encouraging healthy lifestyle habits. , Slated to run all through ...
(Date:10/11/2019)... WASHINGTON (PRWEB) , ... October 11, 2019 , ... Based ... to see a 9 percent increase in deceased organ donors over 2018. Through August ... Procurement and Transplantation Network (OPTN) national database . At this pace, the Association ...
(Date:10/10/2019)... ... October 10, 2019 , ... Ovation Fertility is once again ... reproductive medicine, with six abstracts accepted for poster presentations at the ASRM 2019 ... 12-16, 2019, in Philadelphia. , “Ovation will have a prominent presence in the ...
Breaking Medicine Technology:
(Date:10/15/2019)... SACRAMENTO, Calif. (PRWEB) , ... October 15, 2019 , ... ... Brightwood locations began to shut down in late 2018 . Students who started ... For a time, it seemed as if these students would have to start over. ...
(Date:10/11/2019)... ... 11, 2019 , ... Inland Detox, Inc. has just moved to a new ... views of the Temecula Valley and it’s the perfect place for long-term residential ... private rooms as well as double occupancy rooms, a 2nd home where all treatment ...
(Date:10/10/2019)... ... October 10, 2019 , ... Caring.com, a leading senior care referral service with ... Places for Seniors to Live. All 50 states and 302 cities in the U.S. ... workforce development. , According to the U.S. Census Bureau , almost 20 ...
(Date:10/8/2019)... ... , ... SoCal Adolescent Wellness announces the opening of a second location in ... to better serve the families in Orange County," said Becca Moody, CEO of SoCal ... impact this pre-intervention program has on the lives of the adolescents and families we ...
(Date:10/8/2019)... ... October 08, 2019 , ... Drs. Joel Rosenlicht and Ryaz ... teeth restore their smiles with long-lasting dental implants . Placing over 750 ... 3D Cone Beam CT imaging, X-Guide™ software and Yomi® robotic-assisted technology to plan ...
Breaking Medicine News(10 mins):